HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Chanel

This article was originally published in The Rose Sheet

Executive Summary

Chanel: Anti-Cernes Quick Cover waterproof concealer "covers dark spots and blemishes" while "evening out skin tone," Chanel said. Ombre Creme Satin eye colour "dries to a satin-smooth finish," the company said. Both products are formulated with "light-reflective" Lumioptic pigments to "minimize the appearance of fine lines and wrinkles," while organic esters hydrate the eye area. Eye colour shades include Ivory Silk, Pink Chiffon and Blue Organza. Quick Cover will be available in Soft Beige, Intense Beige, Medium Beige and Candlelight. On-counter in May, the concealer will be priced at $32.50, while the eyeshadow will cost $30. In addition, the company will repeat its Lumiere du Corps Body Shine all-over body powder seasonal offering in 1997. The powder will be available from May to July for $42.50...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel